Sentinel lymph node (SLN) mapping, as introduced for the management of breast cancer by Giuliano et al., is currently regarded as the standard of care for staging of the axilla.[@CR1],[@CR2] In general, a combination of radioactive colloid and blue dye is used. However, this exposes patients and caregivers to ionizing radiation, and blue dyes cannot be seen through skin and fatty tissue. Nonetheless, in recent trials, SLN identification rates of 95--97% are achieved when using this combination, and use of only 1 agent results in significantly lower identification rates.[@CR3]--[@CR6]

Recent preclinical and clinical data have demonstrated that near-infrared (NIR) fluorescence imaging using the NIR fluorescence agent indocyanine green (ICG) enables real-time transcutaneous and intraoperative visualization of lymphatic channels and detection of the SLN.[@CR7]--[@CR14] Therefore, NIR fluorescence imaging could provide an alternative for, or an addition to, conventional techniques used for SLN mapping. However, to date, clinical data are lacking a direct comparison of NIR fluorescence to the combination of radioactive tracer and blue dye. Also, even though ICG is the only fluorescent agent currently available in the clinic, it is not an optimal lymphatic tracer. Previous preclinical work has demonstrated that adsorption of ICG to human serum albumin (HSA, complex is ICG:HSA) increases the fluorescence intensity and the hydrodynamic diameter, thereby providing improved detection and better retention in the SLN.[@CR15]

Recently, first in-human clinical testing of ICG:HSA was performed.[@CR14] The fluorescence-assisted resection and exploration (FLARE) imaging system, developed by our group and used in the trial, is a general-purpose optical imaging platform that provides the surgeon with 2 independent NIR fluorescence channels (centered at 700 and 800 nm) to see otherwise invisible structures within the surgical field.[@CR14],[@CR16] The first generation of FLARE was large, expensive to build, and had a heavy imaging head that required a specially designed articulated arm.[@CR14] This prevented shipment of FLARE to researchers around the world, and therefore impeded efficient scientific investigation. During the first in-human clinical testing of FLARE, it also became apparent that contrast agents for SLN mapping were not yet optimal. The goals of the present study were to develop a miniaturized version of FLARE, termed Mini-FLARE, and to determine optimal lymphatic tracer dosing for SLN mapping in breast cancer.

Methods {#Sec1}
=======

Mini-FLARE Imaging System {#Sec2}
-------------------------

A detailed description of the Mini-FLARE imaging system and in vitro characterization is provided in Supplementary Data. For sterile usage in the operating room, a 0.118-in. thick acrylic splash shield having 95% optical transmission at 800 nm was hermetically bonded to a clear plastic drape and sterilized (Medical Technique, Inc., Tucson, AZ).

Preparation of Indocyanine Green Adsorbed to Human Serum Albumin {#Sec3}
----------------------------------------------------------------

ICG (25-mg vials) was purchased from Pulsion Medical Systems (Munich, Germany) and was resuspended in 10 cc of sterile water for injection to yield a 2.5-mg/ml (3.2-mM) stock solution. Various amounts of this stock solution were transferred to a 50-cc vial of Cealb (20% human serum albumin \[HSA\] solution; Sanquin, Amsterdam, The Netherlands) to yield ICG in HSA (ICG:HSA) at a final concentration of 50 μM, 100 μM, 200 μM, 400 μM, 500 μM, 600 μM, 800 μM, or 1000 μM. To obtain a final concentration of 800 and 1000 μM, ICG was resuspended in 5 cc of sterile water, to yield a 6.4-mM stock solution prior to dilution.

Preclinical Characterization {#Sec4}
----------------------------

Animals were studied under the supervision of approved institutional protocol. Female Yorkshire pigs (E.M. Parsons and Sons, Hadley, MA) averaging 35 kg were induced with 4.4-mg/kg intramuscular Telazol (Fort Dodge Labs, Fort Dodge, IA), intubated, and maintained with 2% isoflurane (Baxter Healthcare, Deerfield, IL). Vital signs were monitored continuously. Excitation fluence rate for white light and 800-nm excitation light were 26,600 lux and 7.7 mW/cm^2^, respectively. Also 100 μL of the specified ICG:HSA solution was injected intradermally. ICG concentration of the ICG:HSA complex was systematically increased from 10 to 500 μM to explore the counteracting effects of NIR fluorophore quenching at the injection site and NIR fluorophore dilution within the lymphatic channels.

Dose-Optimization Clinical Trial {#Sec5}
--------------------------------

Details of the initial 6-patient pilot study of breast cancer SLN mapping using ICG:HSA and Mini-FLARE is provided in the Supplementary Data. The 24-patient dose-escalation clinical trial was approved by the Medical Ethics Committee of the Leiden University Medical Center and was performed in accordance with the ethical standards of the Helsinki Declaration of 1975. All patients who had planned to undergo a SLN procedure for invasive breast cancer or extensive high-risk carcinoma in situ were eligible for participation in the study. Patients had clinically negative axillary nodes as assessed by palpation and ultrasonography. Exclusion criteria were pregnancy, lactation, or an allergy to iodine, shellfish, or indocyanine green.

A total of 24 consecutive patients were included. All patients gave informed consent and were anonymized. Patients received the standard-of-care SLN procedure. For our institution, this implies 1 periareolar injection of approximately 100 MBq ^99m^Technetium-nanocolloid (mean ± S.D. = 99.6 ± 5.8 MBq) the day before surgery. Before the start of the operation, 1 ml of patent blue V was injected peritumorally or periareolarly. Choice of the injection site was left to the surgeon. Directly after patent blue injection, 1.6-ml ICG:HSA was administered as 4 injections at the same location as the patent blue injections. After surgical scrub and sterile covering of the operation field, NIR fluorescence imaging was performed with the imaging head of the Mini-FLARE at approximately 30-cm distance to the surgical field.

The surgical technique consisted of percutaneous assessment of NIR fluorescent signal in the breast and the axilla prior to skin incision. The location and length of the axillary skin incision was determined by the surgeon. Assessment of the surgical field using NIR fluorescence was applied continuously throughout the SLN procedure and surgical exploration. If the SLN was not easily detected by NIR fluorescence, the gamma probe was used to provide direction for surgical exploration. Camera exposure was between 5 and 250 ms as indicated. A SLN exhibiting a signal-to-background ratio (SBR) ≥ 1.1 in situ was considered positive by NIR fluorescence. Background was chosen as an area within the surgical field, directly adjacent (within 1--2 cm) to the SLN.

Routine histopathological frozen analysis of SLNs was performed during surgery. If the patient participated in the After Mapping of the Axilla Radiotherapy or Surgery (AMAROS) trial and was randomized to the radiotherapy arm, no intraoperative frozen analysis was performed. SLNs were fixed in formalin and embedded in paraffin for routine hematoxylin, eosin, and immunohistopathological staining for AE1/AE3 at 3 levels, with an interval of 150--250 μm, according to the Dutch guidelines for SLN analysis. Patients underwent an axillary lymph node dissection if the SLN was found to contain metastases, except for those patients who participated in the radiotherapy arm of the AMAROS trial. If isolated tumor cells (ITCs) were found (\<0.2 mm), no axillary lymph node dissection was performed.

Statistical Analysis {#Sec6}
--------------------

For statistical analysis, SPSS statistical software package (Version 16.0, Chicago, IL) was used. Graphs were generated using GraphPad Prism Software (Version 5.01, La Jolla, CA). To compare the SBR between concentration groups, a one-way analysis of variance (ANOVA) was performed with pairwise comparison with least squares difference (LSD) adjustment for multiple testing. When the assumption of homogeneity of variance was violated (Levene's test), a log10 transformation was applied. All statistical tests were 2-tailed and *P* \< .05 was considered significant.

Results {#Sec7}
=======

Design of the Mini-FLARE Imaging System and In Vitro Characterization {#Sec8}
---------------------------------------------------------------------

The Mini-FLARE imaging system (Fig. [1](#Fig1){ref-type="fig"}a) is composed of a small portable electronics cart and a counterweighted pole stand that supports the imaging head. Unlike FLARE, Mini-FLARE uses a flexible gooseneck arm, which permits positioning of the imaging head at extreme angles virtually anywhere over the surgical field. The only consumable for Mini-FLARE is a specially designed acrylic splash plate that is hermetically sealed to a plastic drape. Using sterile technique, the shield/drape is inserted into the imaging head, locked into place, and the drape is unfolded to encase the imaging head and imaging system pole stand (Fig. [1](#Fig1){ref-type="fig"}b). Optical light paths for white light (i.e., color video images) and the 2 semi-independent NIR fluorescence channels, 1 centered at 700 nm emission and the other at 800 nm emission, are shown in Fig. [1](#Fig1){ref-type="fig"}c.Fig. 1The Mini-FLARE portable near-infrared fluorescence imaging system. **a** Imaging system, composed of electronics/monitor cart and counterweighted imaging system pole. **b** Sterile drape/shield attached to the imaging head with other major parts identified. **c** Excitation and emission light paths, and filtration for the Mini-FLARE imaging system. DM, 650 nm dichroic mirror

Technical specifications of Mini-FLARE are detailed in Table [1](#Tab1){ref-type="table"}. Of note, the working distance is up to 13 in. away from the patient, with field-of-view adjustable from 4.7 in. (12 cm) to 2 in. (5 cm) simply by moving the device toward or away from the surgical field. The cart occupies a volume of only 9.7 ft^3^, and weighs only 272 lb. A 6-pedal footswitch and autofocus circuit permit hands-free operation. The cost of all parts is \~\$40,000.Table 1Mini-FLARE imaging system specificationsCategory/specificationDescriptionPhysical SizeMobile cart: 24 in. W × 24 in. D × 29 in. H; mast height: 76.5 in. WeightCart: 272 lb, including all electronicsArm: 95 lb, including, stand, gooseneck, and imaging headImaging head: 8.8 lb Arm and standFlexible arm; reach: 27--64 in. from floor, 42 in. from center of stand. Center of stand up to 11 linear ft from cartElectrical Voltage and plug120 V AC, 60 Hz; single NEMA 5--15 120 V/15 A AC plug Current5 A max GroundingIsolation transformer for all components; redundant chassis grounding Leakage current\<300 μA (per AAMI/IEC No. 60601)Sterility ShieldDisposable acrylic shield with ≥95% transmission DrapeDisposable, custom-fit plastic drape bonded to shieldLight source HousingAnodized aluminum with integrated liquid cooling ElementsCustom 25-mm circular LED arrays w/integrated linear drivers ElectronicsCustom control board with embedded microcontroller Fluence rates26,600 lux white light (400--650 nm), 1.08 mW/cm^2^ of 700 nm (656--678 nm) excitation light, 7.70 mW/cm^2^ of 800 nm (745--779 nm) excitation lightOptics Working distance4--13 in. (10--32 cm) from patient (reverse telephoto) Field-of-view12 cm W × 9 cm H at 13 in. working distance Emission/reflectance channelsColor video (400--650 nm), 700 nm fluorescence (689--725 nm), 800 nm fluorescence (800--848 nm), all with simultaneous acquisition Pixel resolution640 × 480 for each camera System resolution320 × 320 μm (*x*, *y*) Display refreshUp to 15 Hz simultaneous acquisition on both cameras NIR exposure timeAdjustable from 100 μs to 8 sHands-free OpticsAutomatic focus Control6-pedal footswitchMonitors Number3 cart-mounted 20 in.: 2 for operator and 1 for surgeon

Preclinical Optimization of NIR Fluorescent Lymphatic Tracers {#Sec9}
-------------------------------------------------------------

Our group has previously reported that ICG (and ICG:HSA) exhibits intense quenching (i.e., reduction of fluorescence emission) as its concentration is increased.[@CR15] That is, increasing concentration actually decreases fluorescence, so there would theoretically be no benefit to injecting high concentration for SLN mapping. This effect is demonstrated vividly in Fig. [2](#Fig2){ref-type="fig"}a (left), where the injection site becomes dramatically less fluorescent as concentration increases. As a general rule, if the concentration is high enough to see green color at the injection site, ICG fluorescence is severely quenched.Fig. 2Optimization of ICG:HSA dose as a function of the complex trade-off between fluorescence quenching at the injection site and dilution of fluorophore in lymphatic channels. **a** Preclinical studies in Yorkshire pigs. Subcutaneous injection sites (*left*; *white arrows*) showing quenching and resected SLNs (*right*) showing NIR fluorophore dilution for increasing concentrations of ICG:HSA. For each are displayed color video (*left columns*) and 800 nm NIR fluorescence (*right columns*) images obtained using 760 nm excitation light at 7.7 mW/cm^2^. All camera exposure times were 45 ms. Data are representative of *n* = 3 pigs. **b** Optimization of ICG:HSA dose for breast cancer SLN mapping: Signal-to-background ratio (mean ± SD) of the SLNs (ordinate) as a function of injected dose of ICG:HSA (abscissa) in women undergoing SLN mapping for breast cancer. Statistical comparisons are: 200 vs. 400 μM, *P* = .001; 200 vs. 500 μM, *P* = .001; 200 vs. 600 μM, *P* \< .0001; 200 vs. 800 μM, *P* = .001; 1000 vs. 400 μM, *P* \< .0001; 1000 vs. 500 μM, *P* \< .0001; 1000 vs. 600 μM, *P* \< .0001; 1000 vs. 800 μM, *P* \< .0001. The SBRs of the 400, 500, 600, and 800 μM concentration groups were not significantly different, although a trend was found favoring the 600 μM concentration group (500 vs. 600, *P* = .06)

Importantly, we have recently discovered that dilution of the injected NIR fluorophore as it travels through the lymphatic system and mixes with lymph counteracts the effect of quenching and results in signal in the SLN that increases with concentration, even when the injection site is barely fluorescent (Fig. [2](#Fig2){ref-type="fig"}a, right). This suggests that there will be an "optimal" concentration of injected NIR fluorophore such that final signal in the SLN is as high as possible.

Optimization of ICG:HSA Dose in Women Undergoing SLN Mapping for Breast Cancer {#Sec10}
------------------------------------------------------------------------------

This study aimed to test the feasibility of NIR fluorescence in SLN detection, using ICG:HSA and the Mini-FLARE, in direct comparison with the conventional lymphatic tracers radiocolloid and patent blue. A total of 24 consecutive breast cancer patients underwent standard-of-care SLN mapping with the addition of preoperative ICG:HSA injection and subsequent intraoperative NIR fluorescence imaging. Patient and tumor characteristics are provided in Table [2](#Tab2){ref-type="table"}. Use of the Mini-FLARE during surgery did not interfere with the standard of care. Average time between ICG:HSA injection and skin incision was 16 ± 3 min (Table [3](#Tab3){ref-type="table"}). In all patients (*N* = 24), NIR fluorescence imaging enabled visualization of the SLN (Fig. [3](#Fig3){ref-type="fig"}). A total of 35 SLNs were identified, which were all radioactive and NIR fluorescent (Table [3](#Tab3){ref-type="table"}). There were 5 SLNs from 4 patients that did not have blue staining from patent blue. In all patients, the NIR fluorescence signal in the SLN was detected before patent blue. Average time between skin incision and resection of the first SLN was 17 ± 5 min. After all nodes detected using NIR fluorescence were resected, the axilla was systematically inspected for any remaining radioactivity. No additional radioactive nodes were identified that were not detected by NIR fluorescence. No adverse reactions associated with the use of ICG:HSA or the Mini-FLARE occurred. Two patients experienced a wound infection requiring antibiotics, and one patient underwent surgical re-exploration because of an expanding hematoma following axillary lymph node dissection (Table [3](#Tab3){ref-type="table"}).Table 2Patient and tumor characteristicsCharacteristic*N*%Age (median, range)59.5 (33--81)Menopausal state Premenopausal521 Postmenopausal1979Body mass index (median, range)25 (18--38)Skin type II417 III2083Previous breast surgery^a^313Multifocality417Tumor side Left1458 Right1042Tumor localization Central521 Lower inner14 Lower outer14 Upper inner625 Upper outer1146Type of operation Ablation938 Wide local excision1563Pathological tumor size (median, range)15 (3--35)Histological type Infiltrating ductal adenocarcinoma1875 Infiltrating lobular adenocarcinoma28 Ductal carcinoma In Situ417Histological grade I313 II1354 III833Receptor status^b^ ER + HER2−1667 ER + HER2+313 ER − HER2−14 Missing^c^417^a^Previous breast surgery: silicone breast implantation, breast reduction, and re-excision^b^HER2 status was determined using the chromogenic in situ hybridization (CISH) kit of Zymed (Invitrogen, Carlsbad, CA)^c^Not applicable in 4 patients with ductal carcinoma in situTable 3SLN identification resultsCharacteristic*N*%Injection site patent blue and ICG:HSA Periareolar2083 Peritumoral417SLN detection Number of SLNs identified35 Average number of SLNs identified (range)1.45 (1--3)Method of detection Radioactive35100 Blue3086 Near-infrared fluorescence35100Average time between injection of ICG:HSA and skin incision (SD) (minutes)16 ± 3Average time between skin incision and SLN resection (SD) (minutes)17 ± 5Histology Negative2674 Isolated tumor cells39 Micrometastases00 Macrometastases617Axillary treatment None1667 Axillary lymph node dissection521 Axillary radiotherapy313Complications No2187 Yes3^a^13*ICG:HSA* indocyanine green adsorbed to human serum albumin, *SLN* sentinel lymph node, *SD* standard deviation^a^Two patients experienced postoperative wound infection requiring treatment with antibiotics, and one patient underwent surgical re-exploration because of an expanding hematoma following axillary lymph node dissectionFig. 3Real-time NIR fluorescence imaging during sentinel lymph node mapping in women with breast cancer: Shown are typical in vivo (*top row*) and ex vivo (*bottom row*; postresection) results from a subject injected with 500 μM ICG:HSA. *White arrow* identifies the SLN. NIR fluorescence (*left*) and pseudocolored (*lime green*) merge with the color video image (*right*). Exposure times were 50 ms for in vivo images and 30 ms for ex vivo images. 760 nm excitation fluence rate was \~7.7 mW/cm^2^ for all images. Scale bars indicate 1 cm

A second objective of this trial was to determine the optimal concentration of injected ICG:HSA for NIR fluorescence SLN mapping, i.e., which concentration provides the highest SBR in the SLN. Because ICG and ICG:HSA exhibit intense quenching as their concentrations are increased (typically above 50 μM), there would theoretically be no advantage to injecting higher doses of ICG:HSA. However, dilution of the lymphatic tracer occurs upon injection in the breast and uptake by the lymphatic system counteracting the quenching effect. To assess the relationship between the concentration of injected NIR fluorescent lymphatic tracer and final SBR in the SLN, patients were allocated to 8 ICG:HSA concentration groups ranging from 50 to 1000 μM. The concentration of ICG:HSA influenced the SBR and showed a normal distribution (Fig. [2](#Fig2){ref-type="fig"}b). The variances of the concentration groups were not equal (Levene's test, *P* = .02). A log10 transformation of the data could account for part of the unequal variances (Levene's test, *P* = .05). A 1-way ANOVA with pairwise comparison with LSD adjustment for multiple comparison showed that the SBRs of the 400, 500, 600, and 800 μM concentration groups were significantly higher than of the 50, 100, 200, and 1000 μM concentration groups (200 vs. 400, *P* = .001; 200 vs. 500, *P* = .001; 200 vs. 600, *P* \< .0001; 200 vs. 800, *P* = .001; 1000 vs. 400, *P* \< .0001; 1000 vs. 500, *P* \< .0001; 1000 vs. 600, *P* \< .0001; 1000 vs. 800, *P* \< .0001). The SBRs of the 400, 500, 600, and 800 μM concentration groups were not significantly different, although a trend was found favoring the 600 μM concentration group (500 vs. 600, *P* = .06). The decline of the SBR in the 1000 μM concentration group was caused by decreased NIR fluorescence signal of the SLN (800 vs. 1000, *P* = .001), which suggests that quenching of ICG indeed occurred in the SLN.

Discussion {#Sec11}
==========

Near-infrared (NIR) fluorescent light in the wavelength range of 700--900 nm is invisible to the human eye. It is also capable of penetrating millimeters into living tissue and is not obscured by autofluorescence. For these reasons, NIR fluorescent light is ideal for image-guided surgery. Indeed, several NIR fluorescence surgical imaging systems are already FDA approved or are in the process of obtaining approval (reviewed in Ref. [@CR17]). The Mini-FLARE camera system used in this study is capable of displaying NIR fluorescence signal in relation to the surgical anatomy and illuminates the surgical field with white light. This enabled the surgeon to perform surgery under direct image guidance.

NIR fluorescence optical imaging using Mini-FLARE offers the advantages of real-time, continuous, high-resolution, and high-sensitivity detection of SLNs, without the need for ionizing radiation. Because NIR light is invisible, there is no staining of the surgical field as with blue dyes, and the class of chemicals in which ICG belongs has a remarkable safety record in humans. ICG:HSA adds approximately \$150 to the cost of a case, but if future studies show that the blue dye and/or Tc-99 m sulfur colloid can be eliminated when using NIR fluorescence, a much larger savings will offset this cost. And, the surgeon can perform the injection procedure only minutes before SLN identification and resection. Although a technologist was used in this first in-human study, Mini-FLARE is equipped with hands-free operation and there is virtually no learning curve because unlike other SLN techniques, the lymphatic tracer can be visualized in real-time throughout the procedure.

An important objective of the study was to optimize NIR fluorescent contrast agent dose for breast cancer SLN mapping. The only clinically available NIR fluorescent lymphatic tracer, albeit approved for other indications, is ICG.[@CR7],[@CR11],[@CR13],[@CR18],[@CR19] We have previously proposed simple mixing of ICG and HSA (ICG:HAS) prior to injection because ICG is a small molecule and like blue dyes can pass through SLNs and exhibit a relatively low quantum yield in aqueous environments.[@CR14],[@CR15] Indeed, the product insert for ICG notes that it rapidly binds albumin when injected intravenously, so premixing merely improves kinetics. Importantly, though, premixing increases quantum yield (i.e., brightness) 3-fold and also results in a final hydrodynamic diameter (\~7 nm) that is better retained in the SLN.[@CR15]

NIR fluorescent signal in the SLN is a complex function of the concentration of the injected NIR lymphatic tracer, the distance between the injection site and the SLN, the volume of ultrafiltrate within the lymphatic channels encountered by the NIR fluorophore, and retention of the NIR fluorophore by the SLN. Of these, only the injection concentration can be controlled. Our study suggested that an optimal ICG:HSA concentration is in the range 400 and 800 μM. In the 1000-μM concentration group, the fluorescence intensity of the SLN and the SBR decreased rapidly, most likely due to quenching. Furthermore, since lymphatic vessels could be visualized percutaneously and directly after incision, particularly in the optimal dose range groups, a more efficient identification of SLNs was facilitated. This is of particular benefit for lymph nodes located deeper in the axilla, which exceed the 1--2 cm depth limit of the technology. These nodes could often be located by following the NIR fluorescent signal of the afferent lymphatic tract, as demonstrated in Supplementary Video 1.

The accuracy of SLN identification using ICG fluorescence was similar to that using conventional radioisotope scanning, as both techniques identified all SLNs and no additional fluorescent lymph nodes were identified. However, blue dye identification was not successful in 5 of 35 (14%) SLNs. These results suggest that patent blue staining can be replaced by NIR fluorescence using ICG:HSA. Replacing patent blue has the additional advantage of absent tattooing of the breast and visual alteration of the surgical field. Moreover, the intrinsic dark color of patent blue dye can obscure the fluorescence intensity of any fluorescent lymphatic tracer. Indeed, in vitro tests using a fixed ICG:HSA concentration showed that addition of patent blue dye decreased NIR fluorescence of ICG:HSA (data not shown). An as yet unanswered question is whether radioisotope scanning can be omitted from the SLN procedure. A larger trial to address whether NIR fluorescence imaging alone can replace blue dyes and/or radiocolloids is ongoing.

In summary, this study demonstrated feasibility and accuracy of NIR fluorescence imaging using ICG:HSA and the Mini-FLARE imaging system for SLN mapping in breast cancer patients. The optimal dose of injected ICG:HSA lies between 400 and 800 μM and can be chosen based on local preparation preferences. For example, in the United States, a dose of 500 μM is most convenient since it requires minimal manipulation of albumin volumes.
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